---
title: "Obefazimod (ABX464) in Ulcerative colitis: Prevalence"
description: "Formulary evidence on Obefazimod (ABX464) in Ulcerative colitis: Prevalence. Topics: United States: 378 per 100,000 and an estimated 1.253 million people with ulcerative colitis; United States: prevalence per 100,000 under alternative case definitions and enrollment periods; United States: prevalence exceeding 400 per 100,000 in North America; United States: Medicare fee-for-service beneficiaries; 6 further topics. 10 evidence topics quoted from 9 sources."
canonical: "https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description/prevalence"
published: "2026-11-18T10:42:55-05:00"
modified: "2026-11-18T10:42:55-05:00"
---

# Obefazimod (ABX464) in Ulcerative colitis: Prevalence

<a id="heading-2.2.1.2.2"></a>

## 2.2.1.2.2 Prevalence of Ulcerative colitis

<a id="topic-2.2.1.2.2-1"></a>

### United States: 378 per 100,000 and an estimated 1.253 million people with ulcerative colitis

> “The age-, sex- and insurance-standardized prevalence per 100,000 population was 721 (95% CI 717 – 726) for IBD, 378 per 100,000 (95% CI 375 – 382) for ulcerative colitis and 305 (95% CI 302 – 308) for Crohn’s disease.”
> “Extrapolated to the 2020 census estimate of 331,449,281 US population, there is an estimated 2.390 million Americans with IBD, 1.253 million with ulcerative colitis and 1.011 million with Crohn’s disease.”
> “Of note, the ratio of ulcerative colitis to Crohn’s disease was higher in Asian (1.6:1) and Hispanic (1.8:1) than in White (1.2:1) or Black (1.2:1) Americans.”

Source: [Lewis et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10592313/)

<a id="topic-2.2.1.2.2-2"></a>

### United States: prevalence per 100,000 under alternative case definitions and enrollment periods

| Prevalence definition | Minimum enrollment | Prevalence per 100,000 (95% CI) |
| --- | --- | --- |
| Primary | 4 years | “378 (375–382)” |
| Secondary | 4 years | “438 (435–441)” |
| Primary | 1 year | “312 (310–314)” |
| Secondary | 1 year | “358 (356–361)” |

Source: [Lewis et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10592313/)

<a id="topic-2.2.1.2.2-3"></a>

### United States: prevalence exceeding 400 per 100,000 in North America

> “UC affects approximately 400 of every 100 000 people in North America.”

Source: [Gros and Kaplan (2023)](https://pubmed.ncbi.nlm.nih.gov/37698559/)

<a id="topic-2.2.1.2.2-4"></a>

### United States: Medicare fee-for-service beneficiaries

> “Among 25 million Medicare fee-for-service beneficiaries, there are approximately 100,000 people with CD (0.40%) and 160,000 people with UC (0.64%).”

Source: [ICER special assessment of Entyvio to inform CMS negotiation (2026)](https://icer.org/wp-content/uploads/2026/03/Entyvio_Final-Evidence-Report_For-Publication_030326.pdf)

<a id="topic-2.2.1.2.2-5"></a>

### United States: moderately to severely active disease, about 22% of patients in a given year (ICER 2020, citing the Crohn's & Colitis Foundation)

> “To estimate the size of the potential candidate populations for treatment, we used an estimate by Turner et al. of the prevalence of individuals with UC in the US of approximately 900,000 patients.”
> “The Crohn’s and Colitis Foundation has reported that approximately 22% of UC patients have moderate-to-severe disease activity in a given year”

Source: [ICER Targeted Immune Modulators for Ulcerative Colitis final evidence report (2020)](https://icer.org/wp-content/uploads/2020/08/ICER_UC_Final_Evidence_Report_101620.pdf)

<a id="topic-2.2.1.2.2-6"></a>

### Moderately to severely active disease at diagnosis: population-based inception cohorts

> “In a cohort of patients diagnosed in Copenhagen county between 1962–93, disease course was characterized as indolent, moderate or aggressive in 13%, 73% and 14% of patients, respectively, within the first 5-years of diagnosis; in the same region, in a cohort of patients diagnosed between 2003–04, early disease activity was characterized as mild in 76%, and moderate-to-severe in 24% (23,24).”

Source: [Fumery et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6658168/)

<a id="topic-2.2.1.2.2-7"></a>

### United States: company estimates of moderate-to-severe patients and advanced therapy use

> “From 2020 to 2025, U.S. advanced therapy usage has increased by approximately 96% from approximately 138,000 advanced therapy patients in 2020 to approximately 271,000 advanced therapy patients in 2025.”
> “We currently estimate that approximately 300,000 moderate-to-severe UC patients in the United States, out of an estimated 500,000 patients, are on conventional therapy or steroids only, and a safe, efficacious, oral therapy will have the unique ability to further penetrate this patient segment.”

Source: [Abivax Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1956827/000195682726000012/abvx-20251231.htm)

<a id="topic-2.2.1.2.2-8"></a>

### United States: advanced therapy use after diagnosis in commercially insured adults, 2007 to 2023

> “Among 3,893 patients with newly diagnosed UC (age at diagnosis, 41±14y; 52% male; 80% White, 7.2% Black and 8.2% Hispanic patients) followed over 4.2±3.0y, 5-year risk of IBD-related hospitalization, colectomy and serious infection was 11%, 6%, and 10%, respectively, with lower risk in Hispanic patients (vs. White patients).”
> “Cumulative 1- and 5y use of advanced therapy was 17% (95% CI, 15–18) and 29% (95% CI, 27–31), respectively (Table 1). In a more contemporary cohort of patients diagnosed in 2019–23, the corresponding rate was 27% (95% CI, 24–29) and 38% (95% CI, 34–41), respectively (aHR, 3.43 [95% CI, 2.86–4.13]) (Figure 2C).”
> “Cumulative 1- and 5y use of TNF antagonists and non-TNF-targeting advanced therapy in the more contemporary cohort was 19% (95% CI, 16–21) and 26% (95% CI, 23–29), and 12% (95% CI, 10–14) and 27% (95% CI, 24–31), respectively.”

Source: [Ahuja et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13456955/)

<a id="topic-2.2.1.2.2-9"></a>

### Global: about 5 million prevalent cases in 2023

> “In 2023, the prevalence of ulcerative colitis was estimated to be 5 million cases around the world, and the incidence is increasing worldwide.”

Source: [Le Berre et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37573077/)

<a id="topic-2.2.1.2.2-10"></a>

### Global: prevalence ranges by epidemiologic stage and projected growth

> “The clear distinctions across stages define the CRs for the incidence and prevalence of IBD”
> “stage 1: CR-I = 0.1–1.2, CR-P = 1.2–10.5; stage 2: CR-I = 3.3–10.6, CR-P = 31.2–100.5; stage 3: CR-I = 18.1–34.1, CR-P = 362.9–660.1 (Fig. 2).”
> “Prevalence remains consistently low in regions classified as stage 1. Prevalence noticeably increases in stage 2 and then rises rapidly in stage 3 (Extended Data Fig. 2).”
> “A slowing of prevalence growth rates was also observed in central difference approximations for both CD and UC (Supplementary Fig. 18c,d).”

Source: [Hracs et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12158780/)

## Related pages
- [Obefazimod (ABX464): Ulcerative colitis](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Terms and abbreviations](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/terms-and-abbreviations.md)
- [Obefazimod (ABX464): Ulcerative colitis](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/executive-summary.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Product information and disease description](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Clinical evidence](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/clinical-evidence.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Economic information and modeling report](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/economics) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/economics.md)
- [Obefazimod (ABX464) in Ulcerative colitis: References](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/references) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/references.md)
